Please enable JavaScript to continue using this application.

Compare $ERAS vs $RYTM | Chartloom

Compare

$ERAS vs $RYTM

Erasca Inc · Rhythm Pharmaceuticals Inc

ERAS

Erasca Inc

RYTM

Rhythm Pharmaceuticals Inc

Compare $ERAS vs $RYTM

Comparing Erasca Inc and Rhythm Pharmaceuticals Inc

ERASErasca Inc

RYTMRhythm Pharmaceuticals Inc

ERASErasca Inc

Market cap

$5.49B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

346.5%

52W performance

559.7%

FCF yield

-1.8%

RYTMRhythm Pharmaceuticals Inc

Market cap

$6.22B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.08x

Rev growth (TTM)

53.5%

YTD performance

-13.6%

52W performance

-9.4%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ERAS

RYTM

Detailed metrics comparison

ERAS

Erasca Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

ERAS$5.49B

RYTM$6.22B

Enterprise Value

ERAS$5.44B

RYTM$6.26B

Price

ERAS$16.03

RYTM$90.78

P/E Ratio

ERASN/A

RYTMN/A

P/S Ratio

ERAS0.00x

RYTM25.93x

EV/Sales

ERAS0.00x

RYTM26.10x

EV/EBITDA

ERAS0.00x

RYTM0.00x

P/B Ratio

ERAS14.25x

RYTM29.41x

P/FCF Ratio

ERASN/A

RYTMN/A

EV/FCF

ERAS-55.50x

RYTM-58.90x

PEG Ratio

ERASN/A

RYTMN/A

Forward P/E (NTM)

ERASN/A

RYTMN/A

Forward P/S (NTM)

ERASN/A

RYTM15.08x

Revenue (TTM)

ERAS$0

RYTM$240M

Revenue Growth (YoY)

ERASN/A

RYTM53.5%

Forward Rev Growth

ERAS959.7%

RYTM77.4%

Gross Margin (TTM)

ERAS0.0%

RYTM70.9%

Operating Margin (TTM)

ERAS0.0%

RYTM0.0%

EBITDA Margin (TTM)

ERAS0.0%

RYTM-83.2%

Net Margin (TTM)

ERAS0.0%

RYTM-87.6%

FCF Margin (TTM)

ERASN/A

RYTM-44.3%

Net Income (TTM)

ERAS$-287M

RYTM$-210M

FCF (TTM)

ERAS$-98M

RYTM$-106M

EPS (TTM)

ERAS-$0.92

RYTM-$3.06

ROE (TTM)

ERAS-8043.0%

RYTM-8048.0%

ROA (TTM)

ERAS-6708.0%

RYTM-4400.0%

ROIC (TTM)

ERAS-8043.0%

RYTM-5656.0%

Cash

ERAS$43M

RYTM$66M

Debt

ERAS$0

RYTM$106M

Net Cash/Debt

ERAS$43M

RYTM$-40M

Current Ratio (TTM)

ERAS8.29x

RYTM3.45x

Quick Ratio (TTM)

ERAS8.08x

RYTM3.00x

Debt/Equity (TTM)

ERAS0.00x

RYTM0.49x

Debt/Assets (TTM)

ERAS0.0%

RYTM0.0%

Interest Coverage (TTM)

ERASN/A

RYTMN/A

Net Debt/EBITDA (TTM)

ERAS0.00x

RYTM0.00x

Beta

ERAS0.67

RYTM2.13

52W Performance

ERAS559.7%

RYTM-9.4%

YTD Performance

ERAS346.5%

RYTM-13.6%

% from 52W High

ERAS-34.0%

RYTM-25.7%

% from 52W Low

ERAS661.5%

RYTM21.9%

Asset Turnover (TTM)

ERAS0.00x

RYTM0.51x

FCF Yield (TTM)

ERAS-1.8%

RYTM-1.7%

Earnings Yield (TTM)

ERAS-5.2%

RYTM-3.4%

Dividend Yield (TTM)

ERASN/A

RYTMN/A

Rule of 40

ERAS0.0

RYTM9.2

EV/GP/RG

ERASN/A

RYTM0.49

Ticker research

View ERAS research View RYTM research

Metric	ERAS Erasca Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$5.49B	$6.22B
Enterprise Value	$5.44B	$6.26B
Price	$16.03	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	25.93x
EV/Sales	0.00x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	14.25x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-55.50x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	15.08x
Revenue & Growth
Revenue (TTM)	$0	$240M
Revenue Growth (YoY)	N/A	53.5%
Forward Rev Growth	959.7%	77.4%
Profitability
Gross Margin (TTM)	0.0%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-83.2%
Net Margin (TTM)	0.0%	-87.6%
FCF Margin (TTM)	N/A	-44.3%
Net Income (TTM)	$-287M	$-210M
FCF (TTM)	$-98M	$-106M
EPS (TTM)	-$0.92	-$3.06
ROE (TTM)	-8043.0%	-8048.0%
ROA (TTM)	-6708.0%	-4400.0%
ROIC (TTM)	-8043.0%	-5656.0%
Financial Health
Cash	$43M	$66M
Debt	$0	$106M
Net Cash/Debt	$43M	$-40M
Current Ratio (TTM)	8.29x	3.45x
Quick Ratio (TTM)	8.08x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	2.13
52W Performance	559.7%	-9.4%
YTD Performance	346.5%	-13.6%
% from 52W High	-34.0%	-25.7%
% from 52W Low	661.5%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.51x
FCF Yield (TTM)	-1.8%	-1.7%
Earnings Yield (TTM)	-5.2%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	9.2
EV/GP/RG	N/A	0.49
Ticker research	View ERAS research	View RYTM research

Valuation

P/S Ratio

ERAS

0.00x

RYTM

25.93x

EV/FCF

RYTM

-58.90x

ERAS

-55.50x

Growth & revenue

Revenue Growth TTM

RYTM

53.5%

Forward Revenue Growth

ERAS

959.7%

RYTM

77.4%

Profitability & performance

Gross Margin

RYTM

70.9%

ERAS

0.0%

ROE

ERAS

-8043.0%

RYTM

-8048.0%

FCF Yield %

RYTM

-1.7%

ERAS

-1.8%

52-Week Performance

ERAS

559.7%

RYTM

-9.4%

Detailed metrics comparison

ERAS

Erasca Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

ERAS$5.49B

RYTM$6.22B

Enterprise Value

ERAS$5.44B

RYTM$6.26B

Price

ERAS$16.03

RYTM$90.78

P/E Ratio

ERASN/A

RYTMN/A

P/S Ratio

ERAS0.00x

RYTM25.93x

EV/Sales

ERAS0.00x

RYTM26.10x

EV/EBITDA

ERAS0.00x

RYTM0.00x

P/B Ratio

ERAS14.25x

RYTM29.41x

P/FCF Ratio

ERASN/A

RYTMN/A

EV/FCF

ERAS-55.50x

RYTM-58.90x

PEG Ratio

ERASN/A

RYTMN/A

Forward P/E (NTM)

ERASN/A

RYTMN/A

Forward P/S (NTM)

ERASN/A

RYTM15.08x

Revenue (TTM)

ERAS$0

RYTM$240M

Revenue Growth (YoY)

ERASN/A

RYTM53.5%

Forward Rev Growth

ERAS959.7%

RYTM77.4%

Gross Margin (TTM)

ERAS0.0%

RYTM70.9%

Operating Margin (TTM)

ERAS0.0%

RYTM0.0%

EBITDA Margin (TTM)

ERAS0.0%

RYTM-83.2%

Net Margin (TTM)

ERAS0.0%

RYTM-87.6%

FCF Margin (TTM)

ERASN/A

RYTM-44.3%

Net Income (TTM)

ERAS$-287M

RYTM$-210M

FCF (TTM)

ERAS$-98M

RYTM$-106M

EPS (TTM)

ERAS-$0.92

RYTM-$3.06

ROE (TTM)

ERAS-8043.0%

RYTM-8048.0%

ROA (TTM)

ERAS-6708.0%

RYTM-4400.0%

ROIC (TTM)

ERAS-8043.0%

RYTM-5656.0%

Cash

ERAS$43M

RYTM$66M

Debt

ERAS$0

RYTM$106M

Net Cash/Debt

ERAS$43M

RYTM$-40M

Current Ratio (TTM)

ERAS8.29x

RYTM3.45x

Quick Ratio (TTM)

ERAS8.08x

RYTM3.00x

Debt/Equity (TTM)

ERAS0.00x

RYTM0.49x

Debt/Assets (TTM)

ERAS0.0%

RYTM0.0%

Interest Coverage (TTM)

ERASN/A

RYTMN/A

Net Debt/EBITDA (TTM)

ERAS0.00x

RYTM0.00x

Beta

ERAS0.67

RYTM2.13

52W Performance

ERAS559.7%

RYTM-9.4%

YTD Performance

ERAS346.5%

RYTM-13.6%

% from 52W High

ERAS-34.0%

RYTM-25.7%

% from 52W Low

ERAS661.5%

RYTM21.9%

Asset Turnover (TTM)

ERAS0.00x

RYTM0.51x

FCF Yield (TTM)

ERAS-1.8%

RYTM-1.7%

Earnings Yield (TTM)

ERAS-5.2%

RYTM-3.4%

Dividend Yield (TTM)

ERASN/A

RYTMN/A

Rule of 40

ERAS0.0

RYTM9.2

EV/GP/RG

ERASN/A

RYTM0.49

Ticker research

View ERAS research View RYTM research

Metric	ERAS Erasca Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$5.49B	$6.22B
Enterprise Value	$5.44B	$6.26B
Price	$16.03	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	25.93x
EV/Sales	0.00x	26.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	14.25x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-55.50x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	15.08x
Revenue & Growth
Revenue (TTM)	$0	$240M
Revenue Growth (YoY)	N/A	53.5%
Forward Rev Growth	959.7%	77.4%
Profitability
Gross Margin (TTM)	0.0%	70.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-83.2%
Net Margin (TTM)	0.0%	-87.6%
FCF Margin (TTM)	N/A	-44.3%
Net Income (TTM)	$-287M	$-210M
FCF (TTM)	$-98M	$-106M
EPS (TTM)	-$0.92	-$3.06
ROE (TTM)	-8043.0%	-8048.0%
ROA (TTM)	-6708.0%	-4400.0%
ROIC (TTM)	-8043.0%	-5656.0%
Financial Health
Cash	$43M	$66M
Debt	$0	$106M
Net Cash/Debt	$43M	$-40M
Current Ratio (TTM)	8.29x	3.45x
Quick Ratio (TTM)	8.08x	3.00x
Debt/Equity (TTM)	0.00x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	2.13
52W Performance	559.7%	-9.4%
YTD Performance	346.5%	-13.6%
% from 52W High	-34.0%	-25.7%
% from 52W Low	661.5%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.51x
FCF Yield (TTM)	-1.8%	-1.7%
Earnings Yield (TTM)	-5.2%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	9.2
EV/GP/RG	N/A	0.49
Ticker research	View ERAS research	View RYTM research